Dexcom (DXCM) Other Non-Current Assets (2010 - 2026)
Dexcom's (DXCM) quarterly Other Non-Current Assets came in at $285.9 million in Q1 2026, up 69.67% year-on-year from $168.5 million in Q1 2025, and up 2.58% on a QoQ basis from $278.7 million in Q4 2025.
Dexcom (DXCM) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Dexcom (DXCM) has 17 years of Other Non-Current Assets data on file, last reported at $285.9 million in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 69.67% year-over-year to $285.9 million in Q1 2026; TTM through Mar 2026 was $285.9 million, a 69.67% increase from a year earlier, with the FY2025 full-year figure at $278.7 million, up 61.1% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $285.9 million, up from $278.7 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for DXCM reached as high as $285.9 million in Q1 2026 and fell as low as $22.8 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $118.1 million across 5 years, with a median of $77.7 million in 2024.
- On a YoY basis, Other Non-Current Assets climbed as much as 348.57% in 2022 and fell as far as 6.44% in 2022.
- Year by year, Other Non-Current Assets stood at $47.1 million in 2022, then soared by 59.24% to $75.0 million in 2023, then surged by 130.67% to $173.0 million in 2024, then jumped by 61.1% to $278.7 million in 2025, then gained by 2.58% to $285.9 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $285.9 million in Q1 2026, $278.7 million in Q4 2025, and $276.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 4.15 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 2.05 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 285.90 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 828.89 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.25 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 164.00 Mn |
| 10 | Steris | 20.59 Bn | 20.16 Bn | 697.10 Mn | 211.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285.90 Mn |
| Dec 31, 2025 | 278.70 Mn |
| Sep 30, 2025 | 276.50 Mn |
| Jun 30, 2025 | 175.50 Mn |
| Mar 31, 2025 | 168.50 Mn |
| Dec 31, 2024 | 173.00 Mn |
| Sep 30, 2024 | 88.20 Mn |
| Jun 30, 2024 | 82.90 Mn |
| Mar 31, 2024 | 77.70 Mn |
| Dec 31, 2023 | 75.00 Mn |
| Sep 30, 2023 | 74.40 Mn |
| Jun 30, 2023 | 66.90 Mn |
| Mar 31, 2023 | 56.60 Mn |
| Dec 31, 2022 | 47.10 Mn |
| Sep 30, 2022 | 33.70 Mn |
| Jun 30, 2022 | 24.80 Mn |
| Mar 31, 2022 | 22.80 Mn |
| Dec 31, 2021 | 10.50 Mn |
| Jun 30, 2021 | 23.30 Mn |
| Mar 31, 2021 | 20.40 Mn |